N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

8 Recruiting

4 Completed trials

2 Sponsors

14 Countries

Phase III

Phase II

Phase I/II

Phase III: 4 Phase II: 3 Phase I/II: 5

Indications tested

Mantle cell lymphoma refractory 2 Marginal zone lymphoma recurrent 1 Waldenstrom´s macroglobulinaemia refractory 1 Diffuse large B-cell lymphoma recurrent 1 Follicular lymphoma stage III 1 Waldenstrom´s macroglobulinaemia recurrent 1 Follicular lymphoma stage II 1 Richter's syndrome 1 Follicular lymphoma stage I 1 Mantle cell lymphoma recurrent 1 Marginal zone lymphoma refractory 1 Diffuse large B-cell lymphoma refractory 1

Sponsors using this IMP

BeOne Medicines AG 11 University Of Cologne 1

All trials

12 total

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre… Recruiting

2025-524366-21-00 Phase III 9 countries BeOne Medicines I GmbH
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P… Recruiting

2024-517131-52-00 Phase III 12 countries BeOne Medicines AG
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Phase I/II 3 countries BeOne Medicines AG
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Patients Treated for Blood Cancers Recruiting

2024-518829-15-00 Phase I/II 1 country BeOne Medicines AG
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients Wi… Recruiting

2024-515593-27-00 Phase III 6 countries BeOne Medicines AG
A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumum… Recruiting

2023-507751-30-00 Phase I/II 5 countries BeOne Medicines AG
Study of BGB-11417 in Patients with Myeloid Malignancies Recruiting

2023-508881-14-00 Phase I/II 4 countries BeOne Medicines AG
A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II-TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZANUBRUTINIB (BGB-3111), A BTK INHIBI-TOR, PLUS… Recruiting

2023-504653-12-00 Phase II 3 countries University Of Cologne
A Phase 2 Study to Investigate Sonrotoclax combined with Zanubrutinib Versus Zanubrutinib alone in Patients With Previously Untreated Chroni… Ended

2024-513970-23-00 Phase II 3 countries BeOne Medicines AG
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i… Ended

2023-506948-17-00 Phase III 9 countries BeOne Medicines AG
Study to evaluate the efficacy and safety of BGB-11417 in participants with Waldenström’s Macroglobulinemia Ended

2023-503235-18-00 Phase II 4 countries BeOne Medicines AG
Study of BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma Ended

2022-500687-35-00 Phase I/II 6 countries BeOne Medicines AG

Showing 1–12 of 12 trials

← All drugs A–Z